Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation

Cancer Research

Volumn 73, Issue 2, 2013, Pages 824-833

  Huang, Shyhmin ^a   Li, Chunrong ^a   Armstrong, Eric A ^a   Peet, Chimera R ^a   Saker, Jarob ^a   Amler, Lukas C ^b   Sliwkowski, Mark X ^b   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; MEHD 7945A; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84872525097     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1611     Document Type: Article

References (34)

1. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33: 369-85.
2. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007;25: 4057-65.
3. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13: 5150-55.
4. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28: 357-60.
5. ChaftJE,OxnardGR, SimaCS, KrisMG,MillerVA, RielyGJ. Diseaseflare after tyrosinekinaseinhibitor discontinuationinpatientswithegfr-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17: 6298-303.
6. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dualagent molecular targeting of the epidermal growth factor receptor (egfr): combining anti-egfr antibody with tyrosine kinase inhibitor. Cancer Res 2004;64: 5355-62.
7. Benavente S, Huang S, Armstrong EA, Chi A, Hsu K-T, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009;15: 1585-92.
8. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of her (erbb) family members. Oncogene 2008;27: 3944-56.
9. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from her-family tyrosine kinase inhibitor therapy by the kinaseinactive her3. Nature 2007;445: 437-41.
10. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. Met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling. Science 2007;316: 1039-43.
11. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K, et al. Her kinase axis receptor dimer partner switching occurs in response to egfr tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res 2010;70: 1989-99.
12. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against her3 and egfr has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20: 472-86.
13. Hsu S-C, Hung M-C. Characterization of a novel tripartite nuclear localization sequence in the egfr family. J Biol Chem 2007;282: 10432-40.
14. KimpleRJ, VasevaAV,CoxAD, BaermanKM,CalvoBF, TepperJE, et al. Radiosensitization of epidermal growth factor receptor/her2äpositive pancreatic cancer is mediated by inhibition of akt independent of ras mutational status. Clin Cancer Res 2010;16: 912-23.
15. Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM. P53 modulates acquired resistance to egfr inhibitors and radiation. Cancer Res 2011;71: 7071-79.
16. Bolderson E, Richard DJ, Zhou B-BS, Khanna KK. Recent advances in cancer therapy targeting proteins involved inDNAdouble-strand break repair. Clin Cancer Res 2009;15: 6314-20.
17. Dittmann K, Mayer C, Rodemann H. Inhibition of radiation-induced egfr nuclear import by c225 (cetuximab) suppresses DNA-pk activity. Radiother Oncol 2005;76: 157-61.
18. Sequist LV, Lynch TJ. Egfr tyrosine kinase inhibitors in lung cancer: An evolving story. Annu Rev Med 2008;59: 429-42.
19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11: 21-28.
20. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human egfr family. J Clin Invest 2008;118: 3574-81.
21. Huang Z, Brdlik C, Jin P, Shepard HM. A pan-her approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 2009;9: 97-110.
22. Vlacich G, Coffey RJ. Resistance to egfr-targeted therapy: a family affair. Cancer Cell 2011;20: 423-25.
23. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced her reprogramming in "resistant" breast carcinoma cells. Cancer Res 2009;69: 2191-94.
24. Campbell MR, Amin D, Moasser MM. Her3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010;16: 1373-83.
25. Li C, Huang S, Armstrong EA, Sliwkowski MX, Amler LC, Harari P. MEHA7945A, a dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma. In: Proceedings of the 103rd Annual meeting of the American Association for Cancer Research; 2012, Chicago, IL. Abstract nr 2721.
26. Saffarian S, Li Y, Elson EL, Pike LJ. Oligomerization of the egf receptor investigated by live cell fluorescence intensity distribution analysis. Biophysical J 2007;93: 1021-31.
27. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. Spatial control of egf receptor activation by reversible dimerization on living cells. Nature 2010;464: 783-87.
28. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG. The epidermal growth factor receptor (egfr) tyrosine kinase inhibitor ag1478 increases the formation of inactive untethered egfr dimers: implication for combination therapy with monoclonal antibody 806. J Biol Chem 2007;282: 2840-50.
29. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mabs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 2005;102: 1915-20.
30. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70: 588-97.
31. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of erbb2 signaling causes resistance to the egfrdirected therapeutic antibody cetuximab. Sci Transl Med 2011;3: 99ra86.
32. Quesnelle KM, Grandis Jr. Dual kinase inhibition of egfr and her2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011;17: 5935-44.
33. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9: 862-73.
34. Dibble CC, Manning BD. A molecular link between akt regulation and chemotherapeutic response. Cancer Cell 2009;16: 178-80.